Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.86 USD | -2.61% |
|
-1.79% | -14.03% |
Jun. 03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
Official Publications
No official publication found
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Official Publications